Zura Bio Limited (NASDAQ:ZURA) Receives $10.75 Average PT from Brokerages

Zura Bio Limited (NASDAQ:ZURA) has earned a consensus recommendation of “Moderate Buy” from the six ratings firms that are presently covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, three have given a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $10.75.

Several equities research analysts have recently commented on the company. Wedbush assumed coverage on Zura Bio in a research note on Monday, February 9th. They set an “outperform” rating and a $15.00 price target for the company. Chardan Capital upped their price target on Zura Bio from $10.00 to $11.00 and gave the stock a “buy” rating in a research note on Monday, March 23rd. Oppenheimer cut their price target on Zura Bio from $16.00 to $15.00 and set an “outperform” rating for the company in a research note on Friday, March 20th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Zura Bio in a research report on Wednesday, April 8th.

Zura Bio Price Performance

Zura Bio stock opened at $3.40 on Wednesday. Zura Bio has a 12 month low of $1.00 and a 12 month high of $7.44. The business has a 50 day simple moving average of $5.04 and a 200-day simple moving average of $5.24. The stock has a market capitalization of $322.60 million, a PE ratio of -3.12 and a beta of 0.03.

Zura Bio (NASDAQ:ZURA) last released its quarterly earnings results on Thursday, May 7th. The company reported ($0.22) EPS for the quarter, missing the consensus estimate of ($0.17) by ($0.05). As a group, equities research analysts anticipate that Zura Bio will post -0.76 EPS for the current year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of ZURA. Bank of America Corp DE raised its position in Zura Bio by 31.9% in the fourth quarter. Bank of America Corp DE now owns 41,222 shares of the company’s stock worth $103,000 after acquiring an additional 9,966 shares in the last quarter. AQR Capital Management LLC purchased a new position in Zura Bio in the first quarter worth $72,000. JPMorgan Chase & Co. raised its position in Zura Bio by 78.7% in the second quarter. JPMorgan Chase & Co. now owns 4,659,951 shares of the company’s stock worth $4,893,000 after acquiring an additional 2,052,732 shares in the last quarter. Jane Street Group LLC purchased a new position in Zura Bio in the second quarter worth $113,000. Finally, Atika Capital Management LLC purchased a new position in Zura Bio in the third quarter worth $1,195,000. Hedge funds and other institutional investors own 61.14% of the company’s stock.

About Zura Bio

Zura Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation protein bioconjugates for therapeutic and diagnostic applications. Leveraging a proprietary platform for site-specific incorporation of non-canonical amino acids, the company aims to create highly targeted conjugates that improve drug delivery, enhance imaging contrast, and reduce off-target toxicity. Zura Bio’s technology is designed to streamline the manufacturing process by enabling precise attachment of payloads—such as cytotoxic drugs or imaging agents—to protein scaffolds without affecting their native structure or function.

The company’s research and development activities center on expanding its platform across multiple therapeutic areas, including oncology, immunology and rare diseases.